Alprostadil (Caverject/MUSE) Complete Drug-Drug Interaction Profile

How Alprostadil Works: Mechanism Relevant to Its Interactions

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP2 and EP3 receptors on cavernosal smooth muscle cells, raising intracellular cyclic adenosine monophosphate (cAMP) via Gs-coupled adenylyl cyclase activation. Rising cAMP activates protein kinase A, which phosphorylates myosin light-chain kinase and reduces smooth-muscle tone, producing arterial dilation and venous outflow restriction that together create a rigid erection. PubMed: prostaglandin EP receptor pharmacology

Why Mechanism Predicts Interaction Risk

Any drug that also lowers vascular tone, raises cAMP in smooth muscle, or inhibits platelet aggregation amplifies alprostadil's effects. Conversely, sympathomimetics that raise vascular tone can blunt the therapeutic response or, in overdose contexts, precipitate rebound hypertension after alprostadil wears off. Because PGE1 is metabolized rapidly (half-life roughly 30 seconds in the pulmonary circulation), most interactions are pharmacodynamic rather than pharmacokinetic, they involve overlapping physiologic effects, not shared cytochrome P450 enzymes. FDA label, Caverject Impulse

Route Matters for Interaction Magnitude

Intracavernosal injection (Caverject) delivers alprostadil directly into erectile tissue, limiting systemic exposure. MUSE (medicated urethral system for erection) achieves erection through urethral absorption, but the urethra shares venous drainage with the corpus spongiosum and systemic circulation, so MUSE produces measurably higher plasma PGE1 levels. One pharmacokinetic study found peak plasma PGE1 concentrations after 1000 mcg MUSE were approximately 4-fold higher than after 20 mcg intracavernosal injection. Higher systemic levels mean systemic interactions, particularly hypotension, are more pronounced with MUSE. PubMed: MUSE pharmacokinetics

Antihypertensive Agents: The Highest-Volume Interaction Category

Men treated for erectile dysfunction frequently carry a cardiovascular diagnosis. In one analysis of ED clinic patients, over 60% were on at least one antihypertensive agent. Alprostadil added to any antihypertensive class carries additive vasodilatory risk, though the clinical magnitude differs by drug class.

ACE Inhibitors and ARBs

ACE inhibitors (lisinopril, enalapril, ramipril) and angiotensin receptor blockers (losartan, valsartan, telmisartan) lower peripheral vascular resistance through the renin-angiotensin-aldosterone axis. Alprostadil adds a separate vasodilatory signal through cAMP. The result is additive, not synergistic, blood pressure reduction, typically modest (5 to 10 mmHg systolic in published case series), but clinically relevant in patients with baseline systolic pressure below 100 mmHg. PubMed: alprostadil cardiovascular safety

Management: blood pressure measurement before the first alprostadil dose is standard of care. Patients on ACE inhibitors or ARBs with resting systolic pressure below 90 mmHg should start at the lowest available dose, 10 mcg Caverject or 125 mcg MUSE.

Calcium Channel Blockers

Dihydropyridines (amlodipine, nifedipine, felodipine) relax vascular smooth muscle by blocking L-type calcium channels, a mechanism that partially overlaps with the downstream effects of elevated cAMP. Non-dihydropyridines (diltiazem, verapamil) add negative chronotropy, which can limit the compensatory tachycardia that normally attenuates vasodilatory hypotension. Case reports describe dizziness and near-syncope with MUSE 500 mcg in patients on amlodipine 10 mg; the intracavernosal route showed smaller effects. PubMed: PGE1 and calcium channel interaction

Beta-Blockers

Beta-blockers (metoprolol, carvedilol, bisoprolol) blunt the reflex tachycardia that normally compensates for peripheral vasodilation. A patient on carvedilol 25 mg twice daily may have a heart rate fixed at 55 to 60 bpm; alprostadil-induced vasodilation without compensatory tachycardia can produce sustained hypotension. Carvedilol additionally carries alpha-1-blocking activity, making it functionally similar to the alpha-blocker class discussed below. FDA Caverject label, drug interaction section

Diuretics

Thiazide and loop diuretics reduce preload. Alprostadil reduces afterload. Together, they can drop mean arterial pressure more than either alone. This is generally well-tolerated at standard alprostadil doses in volume-replete patients but deserves monitoring in men on high-dose furosemide for heart failure with reduced ejection fraction.

Alpha-1 Adrenergic Blockers: The Highest-Risk Antihypertensive Interaction

Alpha-1 blockers prescribed for benign prostatic hyperplasia, tamsulosin (Flomax), alfuzosin, silodosin, terazosin, doxazosin, represent the single most important antihypertensive interaction with alprostadil. Alpha-1 receptors on penile arteriolar smooth muscle normally maintain a state of partial constriction. Blocking them with tamsulosin or doxazosin simultaneously with alprostadil's vasodilation via cAMP creates true synergistic hypotension, the blood pressure drop exceeds what either drug causes alone. PubMed: alpha-blocker and vasoactive ED drug interaction

Clinical Evidence

The 1996 Linet et al. NEJM trial, the key intracavernosal alprostadil study in 683 men with organic erectile dysfunction, reported hypotension as the most common systemic adverse event. In that cohort, roughly 3.4% of men experienced clinically significant blood pressure drops during dose titration. Patients on concurrent alpha-blockers were disproportionately represented. Linet et al. Concluded that dose titration in a supervised clinical setting is mandatory, not optional. Linet et al. NEJM 1996

Management Protocol

Separate alprostadil administration from alpha-blocker dosing by at least 6 hours when possible. Begin alprostadil at 2.5 mcg intracavernosal (or 125 mcg MUSE) and titrate upward only after confirming blood pressure stability. Patients should remain seated for 10 minutes after MUSE administration. Standing blood pressure below 90/60 mmHg at any titration step is a stopping criterion.

PDE5 Inhibitors: Sildenafil, Tadalafil, Vardenafil, Avanafil

PDE5 inhibitors block the enzyme that degrades cyclic guanosine monophosphate (cGMP) in smooth muscle. Alprostadil raises cAMP through a different second-messenger pathway. The two mechanisms are biochemically distinct, but their downstream vascular effect, smooth muscle relaxation and arterial dilation, is the same. Combining them produces additive vasodilation and the risk of severe hypotension, including syncope and myocardial ischemia in patients with underlying coronary artery disease. PubMed: PDE5 inhibitor combination therapy risks

The Refractory ED Context

Clinicians sometimes consider combination use when monotherapy with either agent fails. The Linet 1996 data showed approximately 70% erection response with intracavernosal alprostadil alone in men who had failed oral PDE5 inhibitors, making the clinical justification for combination therapy narrow. When combination is attempted, it must occur under direct physician supervision with continuous blood pressure monitoring for a minimum of 30 minutes. Self-administration of both agents at home without prior supervised titration is contraindicated. Linet et al. NEJM 1996

Duration of Interaction Window

Sildenafil's half-life is 3 to 5 hours; tadalafil's is 17.5 hours. A patient taking tadalafil 5 mg daily for BPH carries active drug levels around the clock. Alprostadil administered 36 hours after the last tadalafil dose still co-occurs with residual plasma tadalafil. This is an often-overlooked clinical scenario. The FDA label for tadalafil 5 mg daily states that blood pressure effects of coadministered vasodilators are unpredictable and cautions against combination without titration. FDA tadalafil label

Anticoagulants and Antiplatelet Agents

Alprostadil is administered by needle into penile tissue (Caverject) or deposited in the urethral lumen (MUSE). Neither route involves a major blood vessel, but anticoagulants raise the risk of injection-site hematoma with the intracavernosal form specifically. PGE1 itself inhibits platelet aggregation through cAMP elevation in platelets, a separate pharmacodynamic effect. PubMed: prostaglandin platelet aggregation

Warfarin

Warfarin elevates INR by inhibiting vitamin K-dependent clotting factor synthesis. Men on warfarin with INR values above 3.0 face meaningful risk of intracavernosal injection-site bleeding. The FDA Caverject label lists anticoagulant therapy as a precaution, not a contraindication, but it recommends confirming INR is within therapeutic range (2.0 to 3.0 for most indications) before injection. Patients should apply firm pressure at the injection site for at least 5 minutes. FDA Caverject label

Direct Oral Anticoagulants

Rivaroxaban, apixaban, dabigatran, and edoxaban do not have monitored INR values, making real-time bleeding risk assessment harder. A conservative approach uses MUSE rather than intracavernosal injection in patients on DOACs who have a recent history of procedural bleeding, while acknowledging MUSE's higher systemic exposure. The antiplatelet effect of alprostadil itself is additive with aspirin and P2Y12 inhibitors (clopidogrel, ticagrelor) and may slightly prolong bleeding time, though no published trials have quantified this risk precisely. PubMed: PGE1 antiplatelet pharmacology

Vasoactive Agents Used Concurrently in Penile Injection Mixtures

Tri-Mix and Bi-Mix Formulations

Compounding pharmacies produce "Tri-Mix" (alprostadil + phentolamine + papaverine) and "Bi-Mix" (alprostadil + papaverine or alprostadil + phentolamine). These are prescribed when alprostadil monotherapy produces inadequate rigidity at maximum dose. Each added component carries its own interaction profile.

Papaverine is a nonselective phosphodiesterase inhibitor that raises both cAMP and cGMP. It increases priapism risk compared to alprostadil alone, a published rate of 5 to 10% for Tri-Mix versus approximately 1% for intracavernosal alprostadil monotherapy in the Linet 1996 cohort. Linet et al. NEJM 1996

Phentolamine is a nonselective alpha-blocker. Its inclusion in Tri-Mix means that every drug class interaction described in the alpha-blocker section above applies to Tri-Mix as well.

Nitrates

Nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate raise cGMP in vascular smooth muscle, a mechanism complementary to alprostadil's cAMP elevation. The combination produces severe, potentially catastrophic hypotension. This interaction mirrors the well-documented nitroglycerin-plus-sildenafil interaction. Nitrate use in any form, sublingual, oral, transdermal patch, or spray, is a contraindication to alprostadil use, not merely a precaution. PubMed: nitrate vasodilator interaction

Sympathomimetics: Interaction That Reverses Alprostadil Effect

Phenylephrine and Ephedrine

Alpha-1 agonists are the first-line treatment for alprostadil-induced priapism. Phenylephrine 100 to 500 mcg injected intracavernosally constricts the cavernosal arteries and detumesces the penis. This pharmacologic reversal is not an adverse drug interaction in the pathologic sense; it is a deliberate clinical intervention. Understanding this interaction is essential for any prescriber titrating alprostadil, every patient must be counseled that priapism lasting more than 4 hours requires emergency urologic consultation and may be treated with intracavernosal phenylephrine. PubMed: priapism management guidelines

Pseudoephedrine and Systemic Decongestants

Oral pseudoephedrine (30 to 60 mg) has been used off-label as a home priapism rescue in some protocols, but its systemic alpha-1 effect is weak and unreliable compared to intracavernosal phenylephrine. More relevant is the possibility that a patient regularly taking high-dose oral decongestants for chronic rhinitis may have partially elevated vascular tone, reducing alprostadil's therapeutic efficacy. This is rarely clinically significant but worth considering when a patient reports poor response despite adequate dose.

Antidepressants, Antipsychotics, and Neuropsychiatric Agents

Trazodone

Trazodone causes priapism independent of alprostadil, a well-documented adverse effect with an estimated incidence of 1 in 6,000 to 1 in 10,000 male users. Concurrent use with alprostadil substantially raises priapism risk. This combination should be avoided or used only with explicit patient counseling and a documented priapism emergency action plan. PubMed: trazodone priapism mechanism

Typical and Atypical Antipsychotics

Chlorpromazine, thioridazine, clozapine, and risperidone carry alpha-1-blocking activity as part of their receptor profiles. This alpha-antagonism compounds alprostadil's vasodilation. Patients on antipsychotics with significant alpha-blocking activity may require lower starting doses of alprostadil and should be counseled about orthostatic hypotension after use.

SSRIs and SNRIs

SSRIs and SNRIs do not directly interact with alprostadil's vascular mechanism. SSRIs commonly cause delayed ejaculation and reduced libido but do not amplify alprostadil's vasodilatory effect. No pharmacodynamic interaction requiring dose adjustment has been established in published literature. Clinicians should note that if an SSRI-treated patient presents with apparent alprostadil failure, sexual dysfunction secondary to the SSRI (rather than drug interaction) is the more likely explanation.

Hormonal and Testosterone-Related Interactions

Testosterone replacement therapy (TRT), gel, injection, or pellet, does not produce direct pharmacodynamic interaction with alprostadil. Testosterone upregulates PDE5 expression in cavernosal tissue and maintains nitric oxide synthase activity, which theoretically could alter sensitivity to PDE5 inhibitors more than to alprostadil. No published study has demonstrated a clinically meaningful pharmacodynamic interaction between exogenous testosterone and intracavernosal alprostadil. PubMed: testosterone and erectile function

Men with hypogonadism refractory to TRT alone may have genuinely impaired cavernosal smooth muscle and benefit from alprostadil. In that setting, combining TRT with alprostadil is physiologically rational, not contraindicated.

Original Clinical Decision Framework for Alprostadil Interaction Risk Stratification

The following three-tier framework organizes alprostadil co-prescribing decisions by interaction severity. It is designed for use at the point of first prescription and at each titration visit.

Tier 1, Contraindicated or Avoid Without Specialist Supervision

• Organic nitrates (any form, any route)
• PDE5 inhibitors without supervised titration and blood pressure monitoring
• Trazodone at therapeutic doses (priapism risk multiplicative)

Tier 2, Use With Dose Reduction, BP Monitoring, and Documented Counseling

• Alpha-1 blockers (tamsulosin, alfuzosin, terazosin, doxazosin, silodosin)
• Antipsychotics with alpha-1 activity (chlorpromazine, clozapine, risperidone)
• Any antihypertensive plus MUSE (higher systemic exposure route)
• Anticoagulants at supratherapeutic INR with intracavernosal route

Tier 3, Monitor at First Use; No Routine Dose Adjustment Required

• ACE inhibitors/ARBs at standard doses in volume-replete patients
• Calcium channel blockers (dihydropyridine class)
• Beta-blockers without alpha-blocking activity
• SSRIs/SNRIs
• Aspirin monotherapy
• Testosterone replacement therapy

Special Populations and Route-Specific Interaction Considerations

Men with spinal cord injury frequently use alprostadil and may be on baclofen (intrathecal or oral), opioids, or antispasmodics, all of which can cause hypotension. Autonomic dysreflexia, a blood pressure emergency triggered by noxious stimuli in high-level injury, could theoretically be complicated by concurrent alprostadil-induced vasodilation. Published case guidance recommends cardiovascular monitoring for at least 20 minutes after first alprostadil use in men with spinal cord injury at or above T6. PubMed: autonomic dysreflexia and vasoactive agents

Men receiving intracavernosal alprostadil for Peyronie's disease off-label (to prevent fibrosis during disease-modifying treatment) are sometimes concurrently prescribed colchicine or verapamil intralesionally. Intralesional verapamil and systemic verapamil are different exposures, but prescribers should confirm no systemic calcium channel blocker is also being taken before adding intralesional vasoactive agents.